DCM
ATRS

DAFNA Capital Management’s Antares Pharma, Inc. ATRS Stock Holding History

DAFNA Capital Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-45,000
Closed -$47K – 97
2016
Q2 		$47K Hold
45,000
– – 0.04% 89
2016
Q1 		$39K Hold
45,000
– – 0.03% 91
2015
Q4 		$54K Hold
45,000
– – 0.05% 75
2015
Q3 		$77K Hold
45,000
– – 0.08% 84
2015
Q2 		$94K Buy
+45,000
New +$109K 0.08% 75

Other funds holding ATRS

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

DAFNA Capital Management's ATRS Position: Q3 2016 in Review

DAFNA Capital Management sold out of Antares Pharma, Inc. (ATRS) in Q3 2016, closing a stake of 45,000 shares — an estimated $47K sold.

DAFNA Capital Management first reported a position in ATRS in Q2 2015 and held it in 5 quarters. The position peaked at $94K in Q2 2015. 67 funds tracked by Wall St. Rank hold ATRS as of Q3 2016.

  • DAFNA Capital Management reported no remaining Antares Pharma, Inc. position as of Q3 2016 after selling out during the quarter.
  • DAFNA Capital Management sold 45,000 Antares Pharma, Inc. shares in Q3 2016, an estimated $47K.
  • DAFNA Capital Management first reported a position in Antares Pharma, Inc. in Q2 2015 and held it in 5 quarters.
  • DAFNA Capital Management's Antares Pharma, Inc. position peaked at $94K in Q2 2015.
  • 67 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2016.

Based on DAFNA Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.